Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Kidney Int ; 89(5): 1062-1074, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-27083283

RESUMEN

Activated Wnt signaling is critical in the pathogenesis of renal fibrosis, a final common pathway for most forms of chronic kidney disease. Therapeutic intervention by inhibition of individual Wnts or downstream Wnt/ß-catenin signaling has been proposed, but these approaches do not interrupt the functions of all Wnts nor block non-canonical Wnt signaling pathways. Alternatively, an orally bioavailable small molecule, Wnt-C59, blocks the catalytic activity of the Wnt-acyl transferase porcupine, and thereby prevents secretion of all Wnt isoforms. We found that inhibiting porcupine dramatically attenuates kidney fibrosis in the murine unilateral ureteral obstruction model. Wnt-C59 treatment similarly blunts collagen mRNA expression in the obstructed kidney. Consistent with its actions to broadly arrest Wnt signaling, porcupine inhibition reduces expression of Wnt target genes and bolsters nuclear exclusion of ß-catenin in the kidney following ureteral obstruction. Importantly, prevention of Wnt secretion by Wnt-C59 blunts expression of inflammatory cytokines in the obstructed kidney that otherwise provoke a positive feedback loop of Wnt expression in collagen-producing fibroblasts and epithelial cells. Thus, therapeutic targeting of porcupine abrogates kidney fibrosis not only by overcoming the redundancy of individual Wnt isoforms but also by preventing upstream cytokine-induced Wnt generation. These findings reveal a novel therapeutic maneuver to protect the kidney from fibrosis by interrupting a pathogenic crosstalk loop between locally generated inflammatory cytokines and the Wnt/ß-catenin signaling pathway.


Asunto(s)
Bencenoacetamidas/farmacología , Inhibidores Enzimáticos/farmacología , Enfermedades Renales/prevención & control , Riñón/efectos de los fármacos , Proteínas de la Membrana/antagonistas & inhibidores , Piridinas/farmacología , Obstrucción Ureteral/tratamiento farmacológico , Proteínas Wnt/metabolismo , Vía de Señalización Wnt/efectos de los fármacos , Acilación , Aciltransferasas , Animales , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Colágeno/genética , Colágeno/metabolismo , Modelos Animales de Enfermedad , Regulación hacia Abajo , Fibroblastos/efectos de los fármacos , Fibroblastos/enzimología , Fibroblastos/patología , Fibrosis , Mediadores de Inflamación/metabolismo , Riñón/metabolismo , Riñón/patología , Enfermedades Renales/etiología , Enfermedades Renales/metabolismo , Enfermedades Renales/patología , Proteínas de la Membrana/metabolismo , Ratones Endogámicos C57BL , Procesamiento Proteico-Postraduccional , Obstrucción Ureteral/complicaciones , Obstrucción Ureteral/metabolismo , beta Catenina/metabolismo
2.
PLoS Pathog ; 10(1): e1003887, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24465207

RESUMEN

To be able to colonize its host, invading Salmonella enterica serovar Typhimurium must disrupt and severely affect host-microbiome homeostasis. Here we report that S. Typhimurium induces acute infectious colitis by inhibiting peroxisome proliferator-activated receptor gamma (PPARγ) expression in intestinal epithelial cells. Interestingly, this PPARγ down-regulation by S. Typhimurium is independent of TLR-4 signaling but triggers a marked elevation of host innate immune response genes, including that encoding the antimicrobial peptide lipocalin-2 (Lcn2). Accumulation of Lcn2 stabilizes the metalloproteinase MMP-9 via extracellular binding, which further aggravates the colitis. Remarkably, when exposed to S. Typhimurium, Lcn2-null mice exhibited a drastic reduction of the colitis and remained protected even at later stages of infection. Our data suggest a mechanism in which S. Typhimurium hijacks the control of host immune response genes such as those encoding PPARγ and Lcn2 to acquire residence in a host, which by evolution has established a symbiotic relation with its microbiome community to prevent pathogen invasion.


Asunto(s)
Proteínas de Fase Aguda/inmunología , Colitis/inmunología , Evasión Inmune , Lipocalinas/inmunología , Proteínas Oncogénicas/inmunología , PPAR gamma/inmunología , Infecciones por Salmonella/inmunología , Salmonella typhimurium/inmunología , Enfermedad Aguda , Proteínas de Fase Aguda/genética , Animales , Línea Celular , Colitis/genética , Colitis/microbiología , Colitis/patología , Humanos , Lipocalina 2 , Lipocalinas/genética , Metaloproteinasa 9 de la Matriz/genética , Metaloproteinasa 9 de la Matriz/inmunología , Ratones , Ratones Noqueados , Proteínas Oncogénicas/genética , PPAR gamma/genética , Infecciones por Salmonella/genética , Infecciones por Salmonella/patología , Salmonella typhimurium/patogenicidad , Receptor Toll-Like 4/genética , Receptor Toll-Like 4/inmunología
3.
Blood ; 117(15): 3974-82, 2011 Apr 14.
Artículo en Inglés | MEDLINE | ID: mdl-21325603

RESUMEN

Catalytic domain variants of activated factor VII (FVIIa) with enhanced hemostatic properties are highly attractive for the treatment of bleeding disorders via gene-based therapy. To explore this in a hemophilic mouse model, we characterized 2 variants of murine activated FVII (mFVIIa-VEAY and mFVIIa-DVQ) with modified catalytic domains, based on recombinant human FVIIa (rhFVIIa) variants. Using purified recombinant proteins, we showed that murine FVIIa (mFVIIa) and variants had comparable binding to human and murine tissue factor (TF) and exhibited similar extrinsic coagulant activity. In vitro in the absence of TF, the variants showed a 6- to 17-fold enhanced proteolytic and coagulant activity relative to mFVIIa, but increased inactivation by antithrombin. Gene delivery of mFVIIa-VEAY resulted in long-term, effective hemostasis at 5-fold lower expression levels relative to mFVIIa in hemophilia A mice or in hemophilia B mice with inhibitors to factor IX. However, expression of mFVIIa-VEAY at 14-fold higher than therapeutic levels resulted in a progressive mortality to 70% within 6 weeks after gene delivery. These results are the first demonstration of the hemostatic efficacy of continuous expression, in the presence or absence of inhibitors, of a high-activity gene-based FVIIa variant in an animal model of hemophilia.


Asunto(s)
Dominio Catalítico/genética , Factor VIIa/genética , Terapia Genética/métodos , Hemofilia A/terapia , Hemostasis/fisiología , Animales , Línea Celular , Dependovirus/genética , Modelos Animales de Enfermedad , Factor VIIa/química , Regulación de la Expresión Génica , Técnicas de Transferencia de Gen , Terapia Genética/mortalidad , Hemofilia A/sangre , Hemofilia A/genética , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Fenotipo , Plásmidos/genética , Estructura Terciaria de Proteína
4.
Blood ; 115(3): 510-8, 2010 Jan 21.
Artículo en Inglés | MEDLINE | ID: mdl-19965654

RESUMEN

Proper thymocyte development is required to establish T-cell central tolerance and to generate naive T cells, both of which are essential for T-cell homeostasis and a functional immune system. Here we demonstrate that the loss of transcription factor Foxp1 results in the abnormal development of T cells. Instead of generating naive T cells, Foxp1-deficient single-positive thymocytes acquire an activated phenotype prematurely in the thymus and lead to the generation of peripheral CD4(+) T and CD8(+) T cells that exhibit an activated phenotype and increased apoptosis and readily produce cytokines upon T-cell receptor engagement. These results identify Foxp1 as an essential transcriptional regulator for thymocyte development and the generation of quiescent naive T cells.


Asunto(s)
Diferenciación Celular/genética , Factores de Transcripción Forkhead/fisiología , Proteínas Represoras/fisiología , Linfocitos T/fisiología , Timo/fisiología , Animales , Apoptosis/genética , Apoptosis/inmunología , Diferenciación Celular/inmunología , Proliferación Celular , Células Cultivadas , Factores de Transcripción Forkhead/genética , Ratones , Ratones Congénicos , Ratones Endogámicos C57BL , Ratones Transgénicos , Fenotipo , Proteínas Represoras/genética , Linfocitos T/metabolismo , Timo/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/fisiología
5.
Mol Ther ; 19(9): 1727-36, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21587210

RESUMEN

Vaccines that aim to expand tumor-specific CD8(+) T cells have yielded disappointing results in cancer patients although they showed efficacy in transplantable tumor mouse models. Using a system that more faithfully mimics a progressing cancer and its immunoinhibitory microenvironment, we here show that in transgenic mice, which gradually develop adenocarcinomas due to expression of HPV-16 E7 within their thyroid, a highly immunogenic vaccine expressing E7 only induces low E7-specific CD8(+) T-cell responses, which fail to affect the size of the tumors. In contrast, the same type of vaccine expressing E7 fused to herpes simplex virus (HSV)-1 glycoprotein D (gD), an antagonist of the coinhibitory B- and T-lymphocyte attenuator (BTLA)/CD160-herpes virus entry mediator (HVEM) pathways, stimulates potent E7-specific CD8(+) T-cell responses, which can be augmented by repeated vaccination, resulting in initial regression of even large tumor masses in all mice with sustained regression in more than half of them. These results indicate that active immunization concomitantly with blockade of the immunoinhibitory HVEM-BTLA/CD160 pathways through HSV-1 gD may result in sustained tumor regression.


Asunto(s)
Linfocitos T CD8-positivos/inmunología , Vacunas contra el Cáncer/inmunología , Inmunoterapia Activa/métodos , Neoplasias/terapia , Proteínas E7 de Papillomavirus/inmunología , Animales , Animales Modificados Genéticamente , Biomarcadores , Linfocitos T CD8-positivos/metabolismo , Regulación de la Expresión Génica , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Neoplasias/inmunología , Neoplasias/metabolismo , Proteínas E7 de Papillomavirus/genética , Proteínas E7 de Papillomavirus/metabolismo , Receptores Inmunológicos/genética , Receptores Inmunológicos/inmunología , Receptores Inmunológicos/metabolismo , Miembro 14 de Receptores del Factor de Necrosis Tumoral/genética , Miembro 14 de Receptores del Factor de Necrosis Tumoral/inmunología , Miembro 14 de Receptores del Factor de Necrosis Tumoral/metabolismo , Transducción de Señal , Glándula Tiroides/inmunología , Vacunación/métodos
6.
J Allergy Clin Immunol ; 124(5): 1088-98, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19895996

RESUMEN

BACKGROUND: Lymphocyte cytosolic protein 2, also known as Src homology 2 domain-containing leukocyte phosphoprotein of 76 kilodaltons (SLP-76), is an essential adaptor molecule in myeloid cells, where it regulates FcepsilonRI-induced mast cell (MC) and FcgammaR- and integrin-induced neutrophil (polymorphonuclear leukocyte [PMN]) functions. SLP-76 contains 3 N-terminal tyrosines at residues 112, 128, and 145 that together are critical for its function. OBJECTIVE: We sought to explore the relative importance of tyrosines 112, 128, and 145 of SLP-76 during MC and PMN activation. METHODS: We examined in vitro MC and PMN functions using cells isolated from knock-in mice harboring phenylalanine substitution mutations at tyrosines 112 and 128 (Y112/128F) or 145 (Y145F). We also examined the effects of these mutations on in vivo MC and PMN activation using models of anaphylaxis, dermal inflammation, and serum-induced arthritis. RESULTS: Mutations at Y112/Y128 and Y145 both interfered with SLP-76 activity; however, Y145F had a greater effect than Y112/128F on most in vitro FcR-induced functions. In vitro functional defects were recapitulated in vivo, where mice expressing Y145F exhibited greater attenuation of MC-dependent passive systemic anaphylaxis and PMN-mediated inflammatory responses. Notably, the Y145F mutation completely protected mice against development of joint-specific inflammation in the MC and PMN-dependent K/B x N model of arthritis. CONCLUSION: Our data indicate that Y145 is the most critical tyrosine supporting SLP-76 function in myeloid cells. Future efforts to dissect how Y145 mediates SLP-76-dependent signaling in MCs and PMNs will increase our understanding of these lineages and provide insights into the treatment of allergy and inflammation.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/genética , Anafilaxia/genética , Artritis/genética , Dermatitis/inmunología , Fosfoproteínas/genética , Anafilaxia/inmunología , Animales , Artritis/inmunología , Artritis/patología , Dermatitis/genética , Integrinas/inmunología , Mastocitos/inmunología , Mastocitos/metabolismo , Ratones , Ratones Mutantes , Mutación/genética , Mutación/inmunología , Neutrófilos/inmunología , Neutrófilos/metabolismo , Receptores de IgE/inmunología , Transducción de Señal/inmunología , Tirosina/genética
7.
J Virol ; 82(17): 8431-41, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18562543

RESUMEN

Herpes simplex virus type 1 (HSV-1) produces oral lesions, encephalitis, keratitis, and severe infections in the immunocompromised host. HSV-1 is almost as common as HSV-2 in causing first episodes of genital herpes, a disease that is associated with an increased risk of human immunodeficiency virus acquisition and transmission. No approved vaccines are currently available to protect against HSV-1 or HSV-2 infection. We developed a novel HSV vaccine strategy that uses a replication-competent strain of HSV-1, NS-gEnull, which has a defect in anterograde and retrograde directional spread and cell-to-cell spread. Following scratch inoculation on the mouse flank, NS-gEnull replicated at the site of inoculation without causing disease. Importantly, the vaccine strain was not isolated from dorsal root ganglia (DRG). We used the flank model to challenge vaccinated mice and demonstrated that NS-gEnull was highly protective against wild-type HSV-1. The challenge virus replicated to low titers at the site of inoculation; therefore, the vaccine strain did not provide sterilizing immunity. Nevertheless, challenge by HSV-1 or HSV-2 resulted in less-severe disease at the inoculation site, and vaccinated mice were totally protected against zosteriform disease and death. After HSV-1 challenge, latent virus was recovered by DRG explant cocultures from <10% of vaccinated mice compared with 100% of mock-vaccinated mice. The vaccine provided protection against disease and death after intravaginal challenge and markedly lowered the titers of the challenge virus in the vagina. Therefore, the HSV-1 gEnull strain is an excellent candidate for further vaccine development.


Asunto(s)
Virus Defectuosos/inmunología , Vacunas contra el Virus del Herpes Simple/inmunología , Herpesvirus Humano 1/inmunología , Herpesvirus Humano 1/fisiología , Replicación Viral/fisiología , Adolescente , Animales , Niño , Femenino , Vacunas contra el Virus del Herpes Simple/efectos adversos , Herpesvirus Humano 1/aislamiento & purificación , Humanos , Inmunización Secundaria/métodos , Ratones , Ratones Endogámicos BALB C , Vacunas Atenuadas/inmunología
8.
J Ultrasound Med ; 28(6): 795-800, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19470820

RESUMEN

OBJECTIVE: This study was designed to determine whether the echogenicity of neoplastic tissues changed as a result of low-intensity insonation and whether such alterations were related to an anti-vascular effect. METHODS: In 21 mice, implanted melanomas were insonated at either 1, 2, or 3 MHz using low-intensity ultrasound (spatial-average temporal-average intensity, 2.1 W/cm(2)). B-mode (mean gray scale) and contrast-enhanced power Doppler (percentage area of flow) measurements were made on each tumor before and after therapy. RESULTS: There was an increase in the echogenicity of the tumors with the increase in the frequency of the therapy beam and an accompanying decrease in tumor vascularity. CONCLUSIONS: Although the mechanisms responsible for the echogenicity change are not fully understood, it appears that an increase in the tumor mean gray scale was, at least in part, related to tissue inhomogeneities formed after disruption of the tumor neovasculature.


Asunto(s)
Melanoma Experimental/diagnóstico por imagen , Terapia por Ultrasonido/métodos , Animales , Modelos Animales de Enfermedad , Femenino , Melanoma Experimental/irrigación sanguínea , Melanoma Experimental/terapia , Ratones , Ratones Endogámicos C3H , Trasplante de Neoplasias , Proyectos Piloto , Distribución Aleatoria , Programas Informáticos , Ultrasonografía Doppler en Color
9.
Acad Radiol ; 15(9): 1133-41, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18692754

RESUMEN

RATIONALE AND OBJECTIVES: The goal was to determine whether the tumor vascular disrupting actions of low-intensity ultrasound were frequency dependent. MATERIALS AND METHODS: The effect of the frequency (1 MHz at 2.2 W/cm2 or 3 MHz at 2.4 W/cm2) of low-intensity ultrasound as a neovascular disrupting modality was investigated in 15 murine melanomas (K1735(22)) insonated for 3 minutes after the intravenous injection of a microbubble contrast agent (Definity). In contrast-enhanced power Doppler observations of each tumor (before and after treatment), measurements were made of the size of the area of the tumor that was perfused with blood containing the ultrasound contrast agent (percentage area of flow [PAF]), and the volume of contrast agent flowing through the unit volume of the tumor (color-weighted fractional area [CWFA]). During insonation of the tumor, the temperature was measured with a fine wire thermocouple in an additional eight mice. RESULTS: The antivascular action of low-intensity ultrasound was significantly enhanced (PAF by 64%; CWFA by 106%) when the tumor was treated with 3-MHz ultrasound rather than 1 MHz (analysis of variance: PAF, P=.02; CWFA, P=.04). The average rate of tumor temperature increase was 2.6+/-1.3 degrees C/min for 1 MHz and 5.0+/-1.7 degrees C/min for 3 MHz; these increases were significantly different (P=.04). CONCLUSIONS: Insonation of the tumor at a higher frequency amplified the heating of the neoplasm and led to greater disruption of the tumor vasculature; 3-MHz ultrasound was more efficacious than 1 MHz for antivascular cancer therapy.


Asunto(s)
Melanoma Experimental/terapia , Neovascularización Patológica/terapia , Terapia por Ultrasonido/métodos , Animales , Temperatura Corporal , Medios de Contraste , Femenino , Fluorocarburos , Ratones , Ratones Endogámicos C3H
10.
Ultrasound Med Biol ; 33(12): 1901-10, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17720299

RESUMEN

This study investigated whether a microbubble-containing ultrasound contrast agent had a role in the antivascular action of physiotherapy ultrasound on tumor neovasculature. Ultrasound images (B-mode and contrast-enhanced power Doppler [0.02 mL Definity]) were made of 22 murine melanomas (K1735(22)). The tumor was insonated (I(SATA) = 1.7 W cm(-2), 1 MHz, continuous output) for 3 min and the power Doppler observations of the pre- and postinsonation tumor vascularities were analyzed. Significant reductions (p = 0.005 for analyses of color-weighted fractional area) in vascularity occurred when a contrast-enhanced power Doppler study occurred before insonation. Vascularity was unchanged in tumors without a pretherapy Doppler study. Histologic studies revealed tissue structural changes that correlated with the ultrasound findings. The underlying etiology of the interaction between the physiotherapy ultrasound beam, the microbubble-containing contrast agent and the tumor neovasculature is unknown. It was concluded that contrast agents play an important role in the antivascular effects induced by physiotherapy ultrasound.


Asunto(s)
Fluorocarburos/uso terapéutico , Melanoma Experimental/terapia , Neovascularización Patológica/terapia , Terapia por Ultrasonido/métodos , Animales , Medios de Contraste/uso terapéutico , Femenino , Melanoma Experimental/irrigación sanguínea , Melanoma Experimental/diagnóstico por imagen , Melanoma Experimental/patología , Ratones , Ratones Endogámicos C3H , Microburbujas , Trasplante de Neoplasias , Neovascularización Patológica/diagnóstico por imagen , Neovascularización Patológica/patología , Ultrasonografía Doppler/métodos
11.
Ultrasound Med Biol ; 32(3): 453-61, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16530105

RESUMEN

This study evaluates the histopathological changes that follow insonation of a neoplasm with physiotherapy ultrasound. In 27 mice (C3HV/HeN strain), a subcutaneous melanoma (K1735(22)) was insonated with continuous physiotherapy ultrasound (1 MHz; spatial-average-temporal-average = 2.3 W cm(-2)). Analyses of contrast enhanced (0.1 mL Optison) power Doppler observations showed that insonation significantly (p < 0.05) increased the avascular area in the neoplasm. The predominant acute effect of insonating the neoplasm was an apparently irreparable dilation of the tumor capillaries with associated intercellular oedema; other immediate effects were haemorrage and increased intercellular fluid. Liquefactive necrosis of neoplastic cells was a delayed effect. There was a high correlation (R2 = 0.91) between the percent area affected on histologic examination and the percent increase in avascularity of the neoplasm in the Doppler study. In conclusion, physiotherapy ultrasound produced histologic changes in the tumor vasculature that were consistent with observations made by contrast enhanced power Doppler ultrasound.


Asunto(s)
Melanoma Experimental/irrigación sanguínea , Neovascularización Patológica/terapia , Modalidades de Fisioterapia , Neoplasias Cutáneas/irrigación sanguínea , Terapia por Ultrasonido/métodos , Albúminas , Animales , Medios de Contraste , Fluorocarburos , Melanoma Experimental/diagnóstico por imagen , Melanoma Experimental/terapia , Ratones , Ratones Endogámicos , Microburbujas , Trasplante de Neoplasias , Neoplasias Cutáneas/diagnóstico por imagen , Neoplasias Cutáneas/terapia , Ultrasonografía Doppler , Ultrasonografía Intervencional
12.
Exp Anim ; 65(1): 53-62, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26558540

RESUMEN

We previously found that deletion of the multifunctional factor ANP32B (a.k.a. SSP29, APRIL, PAL31, PHAPI2) resulted in a severe but strain-specific defect resulting in perinatal lethality. The difficulty in generating an adult cohort of ANP32B-deficient animals limited our ability to examine adult phenotypes, particularly cancer-related phenotypes. We bred the Anp32b-null allele into the BALB/c and FVB/N genetic background. The BALB/c, but not the FVB/N, background provided sufficient frequency of adult Anp32b-null (Anp32b(-/-)) animals. From these, we found no apparent oncogenic role for this protein in mammary tumorigenesis contrary to what was predicted based on human data. We also found runtism, pathologies in various organ systems, and an unusual clinical chemistry signature in the adult Anp32b(-/-) mice. Intriguingly, genome-wide single-nucleotide polymorphism analysis suggested that our colony retained an unlinked C57BL/6J locus at high frequency. Breeding this locus to homozygosity demonstrated that it had a strong effect on Anp32b(-/-) viability indicating that this locus contains a modifier gene of Anp32b with respect to development. This suggests a functionally important genetic interaction with one of a limited number of candidate genes, foremost among them being the variant histone gene H2afv. Using congenic breeding strategies, we have generated a viable ANP32B-deficient animal in a mostly pure background. We have used this animal to reliably exclude mouse ANP32B as an important oncogene in mammary tumorigenesis. Our further phenotyping strengthens the evidence that ANP32B is a widespread regulator of gene expression. These studies may also impact the choice of subsequent groups with respect to congenic breeding versus de novo zygote targeting strategies for background analyses in mouse genetics.


Asunto(s)
Proteínas de Ciclo Celular/metabolismo , Ratones Endogámicos BALB C/genética , Proteínas del Tejido Nervioso/metabolismo , Proteínas Nucleares/metabolismo , Alelos , Animales , Animales Congénicos , Cruzamiento , Proteínas de Ciclo Celular/deficiencia , Femenino , Genes Modificadores/genética , Estudios de Asociación Genética , Histonas/genética , Homocigoto , Masculino , Neoplasias Mamarias Animales/genética , Ratones Endogámicos C57BL , Proteínas del Tejido Nervioso/deficiencia , Proteínas Nucleares/deficiencia , Fenotipo , Polimorfismo de Nucleótido Simple
13.
Eur J Pharm Sci ; 83: 143-54, 2016 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-26709081

RESUMEN

PURPOSE: Overexpression of epidermal growth factor receptor (EGFR) is observed in oral squamous cell carcinoma (OSCC) and is associated with increased proliferation, metastasis and therapeutic resistance. We aim to develop a novel drug delivery system comprised of a photosensitizer Chlorin e6 (Ce6) that is encapsulated in a viral envelope and tagged with anti-EGFR antibody to target OSCC. METHODS: Ce6 was encapsulated in both virosomes (Ce6-Vir) and virosomes tagged with anti-EGFR antibody (Ce6-Vir-EGFR'). In vitro studies were conducted to assess the cellular uptake and bioavailability of the photosensitizer in OSCC cells. Ce6 alone or in constructs was then administered in a hamster cheek pouch model and fluorescence imaging and spectroscopy was performed. RESULTS: In vitro results showed that the uptake of Ce6-Vir-EGFR' was lower than that for Ce6-Vir and Ce6 possibly due to its large size. Nevertheless, in vivo results showed significant tumor specificity of Ce6-Vir-EGFR' compared to Ce6. The tumor to normal mucosa ratio showed that Ce6-Vir-EGFR' can successfully target OSCC lesions and therefore shows potential for use in fluorescence diagnosis of OSCC. CONCLUSIONS: Both the virosome-Ce6 constructs were internalized by OSCC cells and successfully used for fluorescence imaging. Tagging with anti-EGFR antibody further improved the targeting ability toward OSCC.


Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Receptores ErbB/inmunología , Mucosa Bucal/diagnóstico por imagen , Neoplasias de la Boca/diagnóstico por imagen , Fármacos Fotosensibilizantes/administración & dosificación , Porfirinas/administración & dosificación , 9,10-Dimetil-1,2-benzantraceno , Animales , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales/farmacología , Carcinógenos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Mejilla , Clorofilidas , Cricetinae , Fluorescencia , Humanos , Masculino , Microscopía Fluorescente , Mucosa Bucal/metabolismo , Mucosa Bucal/patología , Neoplasias de la Boca/metabolismo , Neoplasias de la Boca/patología , Imagen Óptica , Fármacos Fotosensibilizantes/farmacocinética , Fármacos Fotosensibilizantes/farmacología , Porfirinas/farmacocinética , Porfirinas/farmacología , Virosomas
14.
Exp Hematol ; 44(3): 189-93.e2, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26706195

RESUMEN

Despite the success of BCR-ABL1 tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML), resistance to tyrosine kinase inhibitors remains a therapeutic challenge. One strategy used to overcome resistance is combination of existing BCR-ABL1 tyrosine kinase inhibitors with agents that target alternative pathways. We report that inhibition of isoprenylcysteine carboxylmethyltransferase (Icmt), a key enzyme in the protein prenylation pathway, with the selective inhibitor cysmethynil enhances the effect of BCR-ABL1 tyrosine kinase inhibitors in killing CML cells. Cysmethynil augments tyrosine kinase inhibitor-induced apoptosis in both BCR-ABL1 wild type and BCR-ABL1 kinase domain mutant-expressing cell lines. Importantly, the enhanced apoptosis observed with the combination of cysmethynil and imatinib is significant only in primary CML CD34+ progenitor cells, not normal cord blood progenitor cells. The combination was also selective in inhibiting colony formation in CML CD34+ cells. The enhanced apoptosis appears to be due to combination of immediate and persistent inhibition of MAPK signaling. Consistent with in vitro studies, cysmethynil and imatinib, in combination, enhance the in vivo effects of either drug used alone. We found that simultaneous inhibition of BCR-ABL1 and Icmt may represent a potential therapeutic strategy for CML.


Asunto(s)
Apoptosis/efectos de los fármacos , Proteínas de Fusión bcr-abl/antagonistas & inhibidores , Mesilato de Imatinib/farmacología , Indoles/farmacología , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Proteína Metiltransferasas/antagonistas & inhibidores , Animales , Femenino , Proteínas de Fusión bcr-abl/genética , Proteínas de Fusión bcr-abl/metabolismo , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/enzimología , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Sistema de Señalización de MAP Quinasas/genética , Masculino , Ratones , Células Madre Neoplásicas/enzimología , Células Madre Neoplásicas/patología , Proteína Metiltransferasas/genética , Proteína Metiltransferasas/metabolismo
15.
Gut Microbes ; 7(1): 48-53, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26939851

RESUMEN

Helicobacter pylori have been shown to influence physiological regulation of metabolic hormones involved in food intake, energy expenditure and body mass. It has been proposed that inducing H. pylori-induced gastric atrophy damages hormone-producing endocrine cells localized in gastric mucosal layers and therefore alter their concentrations. In a recent study, we provided additional proof in mice under controlled conditions that H. pylori and gut microbiota indeed affects circulating metabolic gut hormones and energy homeostasis. In this addendum, we presented data from follow-up investigations that demonstrated H. pylori and gut microbiota-associated modulation of metabolic gut hormones was independent and precedes H. pylori-induced histopathological changes in the gut of H. pylori-infected mice. Thus, H. pylori-associated argumentation of energy homeostasis is not caused by injury to endocrine cells in gastric mucosa.


Asunto(s)
Metabolismo Energético , Mucosa Gástrica/metabolismo , Microbioma Gastrointestinal , Helicobacter pylori/metabolismo , Animales , Mucosa Gástrica/microbiología , Ghrelina/metabolismo , Infecciones por Helicobacter/microbiología , Humanos , Insulina/metabolismo , Leptina/metabolismo , Ratones , Péptido YY/metabolismo
16.
Oncotarget ; 6(32): 33769-80, 2015 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-26378050

RESUMEN

The use of BCR-ABL1 tyrosine kinase inhibitors (TKI) has led to excellent clinical responses in patients with chronic phase chronic myeloid leukemia (CML). However these inhibitors have been less effective as single agents in the terminal blast phase (BP). We show that pyrvinium, a FDA-approved anthelminthic drug, selectively targets BP-CML CD34+ progenitor cells. Pyrvinium is effective in inducing apoptosis, inhibiting colony formation and self-renewal capacity of CD34+ cells from TKI-resistant BP-CML patients, while cord blood CD34+ are largely unaffected. The effects of pyrvinium are further enhanced upon combination with dasatinib, a second generation BCR-ABL1 TKI. In a CML xenograft model pyrvinium significantly inhibits tumor growth as a single agent, with complete inhibition in combination with dasatinib. While pyrvinium has been shown to inhibit the Wnt/ß-catenin signalling pathway via activation of casein kinase 1α , we find its activity in CML is not dependent on this pathway. Instead, we show that pyrvinium localizes to mitochondria and induces apoptosis by inhibiting mitochondrial respiration. Our study suggests that pyrvinium is a useful addition to the treatment armamentarium for BP-CML and that targeting mitochondrial respiration may be a potential therapeutic strategy in aggressive leukemia.


Asunto(s)
Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Mitocondrias/metabolismo , Compuestos de Pirvinio/administración & dosificación , Adenosina Trifosfato/química , Animales , Antígenos CD34/metabolismo , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Apoptosis , Crisis Blástica/metabolismo , Quinasa de la Caseína I/metabolismo , Línea Celular Tumoral , Proliferación Celular , Dasatinib/administración & dosificación , Dasatinib/uso terapéutico , Humanos , Concentración 50 Inhibidora , Células K562 , Ratones , Ratones SCID , Trasplante de Neoplasias , Fosforilación , Compuestos de Pirvinio/uso terapéutico , Interferencia de ARN , beta Catenina/metabolismo
17.
Sci Rep ; 5: 8731, 2015 Mar 04.
Artículo en Inglés | MEDLINE | ID: mdl-25736205

RESUMEN

Helicobacter pylori, is an invariably commensal resident of the gut microbiome associated with gastric ulcer in adults. In addition, these patients also suffered from a low grade inflammation that activates the immune system and thus increased shunting of energy to host defense mechanisms. To assess whether a H. pylori infection could affect growth in early life, we determined the expression levels of selected metabolic gut hormones in germ free (GF) and specific pathogen-free (SPF) mice with and without the presence of H. pylori. Despite H. pylori-infected (SPFH) mice display alteration in host metabolism (elevated levels of leptin, insulin and peptide YY) compared to non-infected SPF mice, their growth curves remained the same. SPFH mice also displayed increased level of eotaxin-1. Interestingly, GF mice infected with H. pylori (GFH) also displayed increased levels of ghrelin and PYY. However, in contrast to SPFH mice, GFH showed reduced weight gain and malnutrition. These preliminary findings show that exposure to H. pylori alters host metabolism early in life; but the commensal microbiota in SPF mice can attenuate the growth retarding effect from H. pylori observed in GF mice. Further investigations of possible additional side effects of H. pylori are highly warranted.


Asunto(s)
Metabolismo Energético , Infecciones por Helicobacter/metabolismo , Intestino Grueso/metabolismo , Hormonas Peptídicas/metabolismo , Animales , Índice de Masa Corporal , Quimiocina CCL11/metabolismo , Ghrelina/metabolismo , Infecciones por Helicobacter/microbiología , Helicobacter pylori/fisiología , Interacciones Huésped-Patógeno , Humanos , Insulina/metabolismo , Intestino Grueso/microbiología , Leptina/metabolismo , Ratones Endogámicos C57BL , Microbiota/fisiología , Modelos Biológicos , Péptido YY/metabolismo , Organismos Libres de Patógenos Específicos , Aumento de Peso/fisiología
18.
Contemp Top Lab Anim Sci ; 36(1): 90, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12456194

RESUMEN

Although basal cell adenomas are common in the dog and cat, they are rare in all other domestic animals. A literature search revealed two previous reports in rabbits. A case of basal cell adenoma of a rabbit is presented.

19.
Contemp Top Lab Anim Sci ; 43(1): 8-13, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14984283

RESUMEN

The purpose of this study was to determine whether Freund's complete adjuvant causes adverse effects on the physiology, histology, and activity of rabbits used for polyclonal antibody production. Rabbits in the experimental groups were immunized intradermally and subcutaneously with keyhole limpet hemacyanin with or without Freund's adjuvant. Booster immunizations were administered 28 days after the initial immunizations. No immunizations were administered to rabbits in the control group. Body weight, food consumption, activity, rectal temperature, white blood cell count, corticosterone concentration, and induration around immunization sites were measured. Histologic changes in the lung, kidney, liver, lymph node, and skin were evaluated after euthanasia. There were significant differences in white blood cell count, induration around immunization sites, and lipid droplet deposition in pulmonary microgranulomas in some rabbits that received Freund's adjuvant. These differences did not affect well-being of the rabbits. Freund's complete adjuvant caused no adverse effects on physiologic parameters and activity levels in rabbits; thus, its use in polyclonal antibody production should not be discouraged.


Asunto(s)
Temperatura Corporal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Adyuvante de Freund/farmacología , Inmunización/veterinaria , Análisis de Varianza , Animales , Corticosterona/metabolismo , Ensayo de Inmunoadsorción Enzimática , Técnicas Histológicas , Recuento de Leucocitos , Conejos
20.
Contemp Top Lab Anim Sci ; 37(4): 67-72, 1998 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12456149

RESUMEN

The purpose of the study reported here was to evaluate the applicability of a pulpotomy technique used in human dentistry for canine crown reduction in nonhuman primates. General anesthesia was induced on seven male rhesus monkeys, and their canine teeth were amputated at the level of the occlusal surface of the premolars and incisors, using a water-cooled highspeed dental handpiece and a tapered diamond burr. A pulpal access cavity was established. Teeth with vital pulps were capped with calcium hydroxide, varnish, and amalgam. Disarmed canine teeth were evaluated clinically and radiographically during the subsequent 19 weeks. At the conclusion of this period, the monkeys were euthanatized, and the canine teeth were collected for histomorphologic assessment. At the end of the 19-week period, all 27 teeth had intact amalgam seals, 26 had a normal radiographic periodontal ligament space, and 26 had viable pulp, as determined on the basis of histomorphologic evaluation. Thus, 26 of 27 (96%) of the teeth on which the pulpotomy technique was performed were considered viable and, hence, had a successful outcome.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA